Takeda collaborates to launch wearable-tech depression study
pharmafile | February 23, 2017 | News story | Medical Communications, Research and Development | Takeda, depression, mental health, wearable tech
Takeda and Cognition Kit Limited have announced a collaborative venture to trial the use of an app in the monitoring and assessment of cognitive function in patients suffering from Major Depressive Disorder (MDD). The app is designed to function alongside an Apple Watch for patients to complete cognitive tests during the course of the day.
The app will be tested in a pilot of 30 participants, between the ages of 18 and 65 who have been diagnosed with mild to moderate depression. The study aims to determine how wearable technology compares to the traditional neuropsychological testing and patient reported assessments.
“By combining wearable technology with world leading neuroscience, we’ve created an app that collects real time passive and active high-frequency mental health data,” said Jenny Barnett, Cognition Kit. “Being able to access data regularly from daily life can help clinical decision making. Healthcare professionals can obtain patient data and increase patient engagement in their treatment.”
Cognition Kit announced last year that it had completed a successful study that determined the app was able measure, in a clinical environment cognitive performance. The patients were tasked with completing ‘game-like’ cognitive tests that aimed to test attention, memory, mood and reaction speed.
The collaboration between Takeda and Cognition Kit indicates a breakaway from traditional approaches to patient health by a pharmaceutical firm. However, the wearable health industry is estimated to be worth $2 billon globally so getting into the industry early could prove lucrative in the long run for Takeda.
The results of the study are expected to be released in the first half of 2017.
Ben Hargreaves
Related Content
Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as …
MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …
Karuna Therapeutics submits NDA to FDA for schizophrenia treatment
Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the …
